ClinicalTrials.gg
CompletedNCT00657709Updated Oct 10, 2017Results posted

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

A Phase 3 interventional study of Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1) and Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2) in Serogroup B Meningococcal Meningitis, sponsored by Novartis Vaccines. Completed at 66 sites in 5 countries. Open to participants aged 55 Days to 89 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-10-10.

Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,630
Allocation
Randomized
Ages
55 Days to 89 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Meningitis, Meningococcal by Novartis — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Novartis.

Enrollment
2nd of 30
3,630 · median 707
Started
2008
with 1 other
Phase 3
19 of 32
none open now
Registered
9th of 32
by date

Among the 32 studies in Meningitis, Meningococcal by Novartis, this one is the 2nd largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2008, is one of 19 in phase 3, and was the 9th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 32 studies in Meningitis, Meningococcal by Novartis is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 55 Days to 89 Days · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 32 studies in Meningitis, Meningococcal by Novartis as a file.
02

Study summary

The proposed study was aimed to assess the immunogenicity, safety, tolerability and lot to lot consistency of 3 lots of Novartis Meningococcal B vaccine when given concomitantly with routine infant vaccines.

03

Conditions studied

  • Serogroup B Meningococcal Meningitis

Keywords

  • infant
  • Meningococcal disease
  • prevention
  • vaccination
04

Who can participate

Ages eligible
55 Days to 89 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 2-month old infants (55-89 days, inclusive)

Exclusion criteria

Exclusion Criteria:

  • Prior vaccination with routine infant vaccines (Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib), and Pneumococcal antigens)
  • Previous ascertained or suspected disease caused by N. meningitidis
  • History of severe allergic reaction after previous vaccinations or to any vaccine component;
  • Any serious chronic or progressive disease
  • Known or suspected impairment or alteration of the immune system
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,630 participants (actual)

Study arms

  • Experimental
    rMenB Lot1

    Subjects received one injection of rMenB+OMV NZ (Lot 1) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.

    Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)

  • Experimental
    rMenB Lot2

    Subjects received one injection of rMenB+OMV NZ (Lot 2) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.

    Biological: Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)

  • Experimental
    rMenB Lot3

    Subjects received one injection of rMenB+OMV NZ (Lot 3) at 2, 4, 6 months of age concomitantly with the routinely administered infant vaccines.

    Biological: Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)

  • Active comparator
    Routine

    Subjects received the routinely administered infant vaccines at 2, 4, 6 months of age.

    Biological: Infanrix Hexa · Biological: Prevenar

  • Active comparator
    MenC + Routine

    Subjects received the routinely administered infant vaccines and Men C vaccine at 2, 4 and 6 months of age.

    Biological: Infanrix Hexa · Biological: Menjugate · Biological: Prevenar

Interventions

  • BiologicalSerogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)

    One dose of rMenB Lot concomitantly with the routinely administered infant vaccines

  • BiologicalSerogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)

    One dose of rMenB concomitantly with the routinely administered infant vaccines

  • BiologicalSerogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)

    One dose of rMenB concomitantly with the routinely administered infant vaccines

  • BiologicalInfanrix Hexa

    Routine vaccination

  • BiologicalMenjugate

    One dose of the routinely administered infant vaccines + MenC vaccine

  • BiologicalPrevenar

    Routine vaccination

06

What researchers measure

Primary outcomes

  1. The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination

    The hSBA antibody titer responses, one month after receiving the third vaccination of rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).

    Time frame: one month after the third vaccination

  2. The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)

    The immunogenicity was assessed in terms of the percentages of subjects who had received the three doses of rMenB+OMV NZ (3 lots combined) given concomitantly with routine infant vaccinations and percentages of subjects who received only the routine infant vaccinations as measured by hSBA titer ≥1:5 following rMenB+OMV NZ vaccinations one month after the third vaccination is reported.

    Time frame: one month after the third vaccination

Secondary outcomes

  1. The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (From 3 Lots)

    The immunogenicity was evaluated to assess the consistency of the immune response from three lots of rMenB+OMV NZ in terms of percentage of subjects as measured by hSBA titer ≥1:5 when given to healthy infants at 2, 4, and 6 months of age, at 1 month after the third vaccination.

    Time frame: 1 month after the third vaccination

  2. Geometric Mean Human Serum Bactericidal Activity Titers After the Routine Vaccination Without rMenB OMV NZ

    The immunogenicity was assessed in terms of prevalence of meningococcal B antibodies as measured by the hSBA, at baseline and at one month after the third vaccination, in the subjects that received routine infant vaccines without rMenB+OMV NZ.

    Time frame: 1 Month after the third vaccination

  3. Geometric Mean Concentrations After Three Doses of rMenB+OMV NZ Vaccination (Against the 287-953 Antigen)

    The immunogenicity was evaluated to characterize the immune response against vaccine antigen 287-953, as measured by ELISA at one month after third vaccination.

    Time frame: 1 month after third vaccination

  4. Geometric Mean Concentrations for Antigens (Pertussis Components) for the Routine Vaccinations

    Immunogenicity of the pertussis components (PT, FHA, pertactin) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after third vaccination.

    Time frame: 1 month after third vaccination

  5. Percentages of Subjects With Antibody Response Against the Routine Antigens

    The immunogenicity of routine infant vaccines when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age and of the routine infant vaccines given without rMenB+OMV NZ at 1 month after third vaccination with B pertussis, diptheria and tetanus toxoid, H influenza type b, Hepatitis B antigens was measured by ELISA (Enzyme-linked immunosorbent assay) and for polio type 1, type 2 and type 3 by neutralization test (NT)(\>=1:8). Diptheria and Tetanus: primary endpoint ELISA \>=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA\>=1.0 IU/mL. HepB (HBV):primary endpoint ELISA \>=10 mU/mL. PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.PNC \>=0.35 mcg/ml

    Time frame: 1 Month after third vaccination

  6. Percentages of Subjects With Fourfold Increase in Antibody Concentrations Against the Routine Antigens

    Immunogenicity was assessed in terms of the percentages of subjects with fourfold increase in antibody concentrations against the routine pertussis antigens FHA (Filamentous Hemagglutinin), Pertactin and PT (Pertussis Toxoid).

    Time frame: 5 months

  7. Percentages of Subjects With Fourfold Rise in hSBA Titers After Three Doses of rMenB+OMV NZ Vaccination

    Immunogenicity was assessed in terms of the percentages of subjects with fourfold rise in hSBA titers after the three doses of rMenB+OMV NZ (lot 1 or lot 2 or lot 3) vaccination at 2, 4 and 6 months of age.

    Time frame: 1 Month after third vaccination

  8. Percentage of Subjects With hSBA Titers ≥1:8

    Immunogenicity was assessed in terms of the percentages of subjects achieving hSBA titers ≥1:8 at one month after third vaccination with rMenB (lot 1 or lot 2 or lot 3) against the three vaccine strains.

    Time frame: 1 month after third vaccination

  9. Number of Subjects Reporting Solicited Adverse Events After Receiving Three Doses of rMenB+OMV NZ Vaccine

    The safety and tolerability of three doses of rMenB+OMV NZ when given concomitantly with routine infant vaccines at 2, 4 and 6 months of age was assessed by the number of subjects reporting solicited local and systemic adverse events.

    Time frame: upto 7 days after any vaccination

07

Results

Posted Apr 10, 2015

Participant flow

16 sites in Finland, 28 sites in the Czech Republic, 13 sites in Germany, 6 sites in Austria, 7 sites in Italy.

Participant flow — Overall Study
MilestonerMenB Lot1rMenB Lot2rMenB Lot3RoutineMenC+ Routine
Started833828820659490
Completed810795792645457
Not completed2333281433
Withdrew: Ae or death77671
Withdrew: Withdrawal by subject7151559
Withdrew: Lost to follow-up997121
Withdrew: Protocol violation02012

Outcome measures

PrimaryThe Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination

The hSBA antibody titer responses, one month after receiving the third vaccination of rMenB+OMV NZ vaccination, are reported as geometric mean titers (GMTs).

Time frame:
one month after the third vaccination
Reported as:
Geometric mean · Titers
The Geometric Mean Human Serum Bactericidal Activity (hSBA) Titers After Three Doses of rMenB+OMV NZ Vaccination
TitersrMenB Lot1rMenB Lot2rMenB Lot3
44/76-SL strain (Baseline)1.21 (1.14 to 1.29)1.19 (1.12 to 1.27)1.19 (1.12 to 1.27)
44/76-SL strain one month after 3rd vaccination87 (80 to 95)98 (90 to 106)85 (78 to 93)
5/99 strain (Baseline)1.21 (1.14 to 1.3)1.2 (1.12 to 1.28)1.21 (1.13 to 1.29)
5/99 strain one month after 3rd vaccination598 (550 to 651)681 (626 to 741)607 (558 to 661)
NZ98/254 strain (Baseline)1.03 (1 to 1.06)1.06 (1.03 to 1.1)1.04 (1 to 1.07)
one month after 3rd vaccination15 (13 to 17)14 (12 to 16)15 (14 to 17)
Statistical analysis
  • rMenB Lot1 vs rMenB Lot2 · ANOVA · Hsba gmt ratios: 0.9 · 95% CI 0.81 to 0.9995% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log-transformed titers and both the limits of 95% CIs.
  • rMenB Lot1 vs rMenB Lot3 · ANOVA · Hsba gmt ratios: 1.02 · 95% CI 0.93 to 1.1395% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log-transformed titers and both the limits of 95% CIs.
  • rMenB Lot2 vs rMenB Lot3 · ANOVA · Hsba gmt ratios: 1.14 · 95% CI 1.03 to 1.2795% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log-transformed titers and both the limits of 95% CIs.
  • rMenB Lot1 vs rMenB Lot2 · ANOVA · Hsba gmt ratios: 0.88 · 95% CI 0.78 to 0.9895% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log-transformed titers and both the limits of 95% CIs.
  • rMenB Lot1 vs rMenB Lot3 · ANOVA · Hsba gmt ratios: 0.99 · 95% CI 0.88 to 1.195% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log-transformed titers and both the limits of 95% CIs.
  • rMenB Lot2 vs rMenB Lot3 · ANOVA · Hsba gmt ratios: 1.12 · 95% CI 1.0 to 1.2695% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log-transformed titers and both the limits of 95% CIs
  • rMenB Lot1 vs rMenB Lot2 · ANOVA · Hsba gmt ratios: 1.04 · 95% CI 0.88 to 1.2395% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log-transformed titers and both the limits of 95% CIs.
  • rMenB Lot1 vs rMenB Lot3 · ANOVA · Hsba gmt ratios: 0.96 · 95% CI 0.81 to 1.1395% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log-transformed titers and both the limits of 95% CIs.
  • rMenB Lot2 vs rMenB Lot3 · ANOVA · Hsba gmt ratios: 0.92 · 95% CI 0.78 to 1.0895% CIs for the GMTs ratios was obtained by exponentiating difference of least square means of log-transformed titers and both the limits of 95% CIs.
PrimaryThe Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)

The immunogenicity was assessed in terms of the percentages of subjects who had received the three doses of rMenB+OMV NZ (3 lots combined) given concomitantly with routine infant vaccinations and percentages of subjects who received only the routine infant vaccinations as measured by hSBA titer ≥1:5 following rMenB+OMV NZ vaccinations one month after the third vaccination is reported.

Time frame:
one month after the third vaccination
Reported as:
Number · Percentages of subjects
The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (3 Lots Combined)
Percentages of subjectsrMenB AllRoutine
44/76-SL strain (Baseline)3 (2 to 4)3 (1 to 8)
44/76-SL strain-1 Month after 3rd vaccination100 (99 to 100)3 (1 to 7)
5/99 strain (Baseline)4 (3 to 5)7 (3 to 13)
5/99 strain-1 Month after 3rd vaccination100 (99 to 100)2 (0 to 6)
NZ98/254 strain (Baseline)1 (1 to 2)1 (0.021 to 5)
1 Month after 3rd vaccination84 (82 to 86)2 (0 to 6)
SecondaryThe Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (From 3 Lots)

The immunogenicity was evaluated to assess the consistency of the immune response from three lots of rMenB+OMV NZ in terms of percentage of subjects as measured by hSBA titer ≥1:5 when given to healthy infants at 2, 4, and 6 months of age, at 1 month after the third vaccination.

Time frame:
1 month after the third vaccination
Reported as:
Number · Percentages of subjects
The Percentages of Subjects With hSBA Titer ≥1:5 After Receiving Three Doses of rMenB+OMV Vaccination (From 3 Lots)
Percentages of subjectsrMenB Lot1rMenB Lot2rMenB Lot3Routine
44/76-SL Baseline4 (2 to 6)2 (1 to 4)3 (2 to 6)3 (1 to 8)
44/76-SL-1 Month after 3rd vaccination100 (99 to 100)100 (99 to 100)99 (98 to 100)3 (1 to 7)
5/99 Baseline3 (2 to 5)4 (3 to 7)4 (2 to 7)7 (3 to 13)
5/99-1 Month after 3rd vaccination100 (99 to 100)100 (99 to 100)99 (98 to 100)2 (0 to 6)
NZ 98/254 Baseline1 (0 to 2)2 (1 to 4)1 (0 to 2)1 (0.021 to 5)
1 Month after 3rd vaccination84 (80 to 88)81 (77 to 85)85 (81 to 89)2 (0 to 6)
Statistical analysis
  • rMenB Lot1 vs rMenB Lot2 · Miettinen and Nurminen · Vaccines group differences: 0 · 95% CI -1 to 1The lot-to-lot differences in these percentages and associated 95% CIs were computed for each pair of rMenB+OMV lots.
  • rMenB Lot1 vs rMenB Lot3 · Miettinen and Nurminen · Vaccines group differences: 1 · 95% CI 0 to 2The lot-to-lot differences in these percentages and associated 95% CIs were computed for each pair of rMenB+OMV lots.
  • rMenB Lot2 vs rMenB Lot3 · Miettinen and Nurminen · Vaccines group differences: 1 · 95% CI 0 to 2The lot-to-lot differences in these percentages and associated 95% CIs were computed for each pair of rMenB+OMV lots.
  • rMenB Lot1 vs rMenB Lot2 · Miettinen and Nurminen · Vaccines group differences: 0 · 95% CI -1 to 1The lot-to-lot differences in these percentages and associated 95% CIs were computed for each pair of rMenB+OMV lots.
  • rMenB Lot1 vs rMenB Lot3 · Miettinen and Nurminen · Vaccines group differences: 1 · 95% CI 0 to 2The lot-to-lot differences in these percentages and associated 95% CIs were computed for each pair of rMenB+OMV lots.
  • rMenB Lot2 vs rMenB Lot3 · Miettinen and Nurminen · Vaccines group differences: 1 · 95% CI 0 to 2The lot-to-lot differences in these percentages and associated 95% CIs were computed for each pair of rMenB+OMV lots.
  • rMenB Lot1 vs rMenB Lot2 · Miettinen and Nurminen · Percentage group difference: 3 · 95% CI -2 to 8The lot-to-lot differences in these percentages and associated 95% CIs were computed for each pair of rMenB+OMV lots.
  • rMenB Lot1 vs rMenB Lot3 · Miettinen and Nurminen · Percentage group difference: -1 · 95% CI -6 to 4The lot-to-lot difference in these percentages and associated 95% CIs were computed for each pair of rMenB+OMV lots.
  • rMenB Lot2 vs rMenB Lot3 · Miettinen and Nurminen · Percentage group difference: -4 · 95% CI -9 to 1The lot-to-lot differences in these percentages and associated 95% CIs were computed for each pair of rMenB+OMV lots.
SecondaryGeometric Mean Human Serum Bactericidal Activity Titers After the Routine Vaccination Without rMenB OMV NZ

The immunogenicity was assessed in terms of prevalence of meningococcal B antibodies as measured by the hSBA, at baseline and at one month after the third vaccination, in the subjects that received routine infant vaccines without rMenB+OMV NZ.

Time frame:
1 Month after the third vaccination
Reported as:
Geometric mean · Titers
Geometric Mean Human Serum Bactericidal Activity Titers After the Routine Vaccination Without rMenB OMV NZ
TitersrMenB AllRoutine
44/76 Strain (Baseline)1.15 (1.12 to 1.19)1.12 (1.04 to 1.22)
44/76 Strain-1 Month after third vaccination91 (87 to 95)1.2 (1.1 to 1.31)
5/99 Strain (Baseline)1.18 (1.14 to 1.22)1.21 (1.1 to 1.33)
5/99 Strain-1 Month after third vaccination635 (606 to 665)1.06 (0.97 to 1.17)
NZ98/254 (Baseline)1.05 (1.03 to 1.07)1.01 (0.99 to 1.04)
1 Month after third vaccination14 (13 to 15)1.04 (0.98 to 1.11)
SecondaryGeometric Mean Concentrations After Three Doses of rMenB+OMV NZ Vaccination (Against the 287-953 Antigen)

The immunogenicity was evaluated to characterize the immune response against vaccine antigen 287-953, as measured by ELISA at one month after third vaccination.

Time frame:
1 month after third vaccination
Reported as:
Geometric mean · IU/mL
Geometric Mean Concentrations After Three Doses of rMenB+OMV NZ Vaccination (Against the 287-953 Antigen)
IU/mLrMenB Lot1rMenB Lot2rMenB Lot3rMenB AllRoutine
Baseline22 (21 to 23)22 (21 to 22)22 (21 to 23)22 (21 to 22)21 (20 to 21)
1 Month after 3rd vaccination3149 (2960 to 3352)3484 (3270 to 3712)3103 (2915 to 3304)3370 (3270 to 3472)22 (21 to 23)
SecondaryGeometric Mean Concentrations for Antigens (Pertussis Components) for the Routine Vaccinations

Immunogenicity of the pertussis components (PT, FHA, pertactin) of DTPa-HBV-IPV when given concomitantly with rMenB and PCV7 would be considered non-inferior to that of the routine vaccines given alone if the lower limit of the two-sided CI for the ratio of GMCs one month after third vaccination.

Time frame:
1 month after third vaccination
Reported as:
Geometric mean · IU/mL
Geometric Mean Concentrations for Antigens (Pertussis Components) for the Routine Vaccinations
IU/mLrMenB AllRoutine
FHA (Baseline)9.98 (8.78 to 11)9.28 (8.17 to 11)
1 Month post 3rd vaccination; FHA123 (114 to 133)147 (136 to 158)
Pertactin (Baseline)6.3 (5.52 to 7.17)5.36 (4.71 to 6.11)
1 Month post 3rd vaccination; Pertactin107 (97 to 119)139 (126 to 155)
PT (Baseline)2.82 (2.68 to 2.96)2.82 (2.68 to 2.96)
1 Month post 3rd vaccination; PT41 (37 to 44)51 (46 to 55)
Statistical analysis
  • rMenB All vs Routine · ANOVA · Geometric group difference: 0.84 · 95% CI 0.76 to 0.94GMCs and 95% CIs were constructed by exponentiating (base 10) the least squares means of the log10-transformed titers and their associated 95% CIs.
  • rMenB All vs Routine · ANOVA · Geometric group difference: 0.77 · 95% CI 0.67 to 0.89GMCs and 95% CIs were constructed by exponentiating (base 10) the least square means of the log10-transformed titers and their associated 95% CIs.
  • rMenB All vs Routine · ANOVA · Geometric group difference: 0.8 · 95% CI 0.71 to 0.91GMCs and 95% CIs were constructed by exponentiating (base 10) the least squares means of the log10-transformed titers and their associated 95% CIS.
SecondaryPercentages of Subjects With Antibody Response Against the Routine Antigens

The immunogenicity of routine infant vaccines when given concomitantly with rMenB+OMV NZ at 2, 4, and 6 months of age and of the routine infant vaccines given without rMenB+OMV NZ at 1 month after third vaccination with B pertussis, diptheria and tetanus toxoid, H influenza type b, Hepatitis B antigens was measured by ELISA (Enzyme-linked immunosorbent assay) and for polio type 1, type 2 and type 3 by neutralization test (NT)(\>=1:8). Diptheria and Tetanus: primary endpoint ELISA \>=0.1 (international unit -IU) IU/mL and the secondary endpoint is ELISA\>=1.0 IU/mL. HepB (HBV):primary endpoint ELISA \>=10 mU/mL. PRP-T: primary endpoint ≥ 0.15 mcg/mL and ≥ 1.00 mcg/mL.PNC \>=0.35 mcg/ml

Time frame:
1 Month after third vaccination
Reported as:
Number · Percentages Of Subjects
Percentages of Subjects With Antibody Response Against the Routine Antigens
Percentages Of SubjectsrMenB AllRoutine
Anti-DiphtheriaToxin ≥0.1IU/mL(Baseline)38 (32 to 44)38 (32 to 45)
1 Month post third vaccination;anti-D100 (98 to 100)100 (98 to 100)
Anti-DiphtheriaToxin ≥1.0 IU/mL(Baseline)2 (1 to 5)2 (1 to 5)
1 Month post third vaccination, anti-D≥1.0 IU/mL80 (75 to 85)86 (81 to 90)
Anti-TetanusToxin ≥0.1 IU/mL(Baseline)93 (88 to 96)95 (91 to 97)
1 Month post third vaccination;anti-T100 (98 to 100)100 (98 to 100)
Anti-Tetanus Toxin ≥1.0 IU/mL(Baseline)24 (18 to 30)27 (22 to 33)
1 Month after third vaccination,anti-T≥1.0 IU/mL91 (86 to 94)95 (91 to 97)
Polio 1 ≥1:8 (Baseline)75 (69 to 80)72 (66 to 77)
1 Month post third vaccination;Polio 195 (92 to 98)97 (94 to 99)
Polio 2 (Baseline)68 (62 to 74)69 (63 to 74)
1 Month post third vaccination;Polio 288 (84 to 92)94 (90 to 97)
Polio 3 (Baseline)48 (41 to 54)49 (42 to 55)
1 Month post third vaccination;Polio 397 (94 to 99)98 (95 to 99)
HBV ≥10 mIU/mL (Baseline)22 (17 to 28)15 (10 to 20)
1 Month post third vaccination;HBV98 (95 to 99)100 (99 to 100)
Anti-PRP (HIB) ≥ 0.15 μg/mL(Baseline)54 (47 to 60)55 (49 to 62)
1 Month post 3rd vaccination;anti-PRP ≥ 0.1599 (97 to 100)100 (98 to 100)
Anti-PRP (HIB) ≥ 1.0 μg/mL (Baseline)12 (9 to 17)10 (7 to 15)
1 Month post third vaccination;anti-PRP ≥ 1.079 (73 to 84)79 (73 to 84)
PnC4 ≥0.35μg/mL (Baseline)2 (0 to 4)2 (1 to 5)
1 Month post third vaccination;PnC498 (95 to 99)100 (98 to 100)
PnC 6B ≥0.35μg/mL (Baseline)14 (10 to 19)16 (12 to 22)
1 Month post third vaccination;PnC 6B90 (85 to 93)88 (83 to 92)
PnC 9V ≥0.35μg/mL (Baseline)4 (2 to 7)3 (1 to 6)
1 Month post third vaccination;PnC 9V100 (98 to 100)100 (98 to 100)
PnC 14 ≥0.35μg/mL (Baseline)33 (27 to 39)38 (31 to 44)
1 Month post third vaccination;PnC 1496 (93 to 98)97 (94 to 99)
PnC 18C ≥0.35μg/mL (Baseline)10 (7 to 15)17 (12 to 22)
1 Month post third vaccination;PnC 1898 (96 to 100)99 (97 to 100)
PnC 19F ≥0.35μg/mL (Baseline)20 (15 to 26)21 (16 to 27)
1 Month post third vaccination;PnC 1996 (93 to 98)96 (93 to 98)
PnC 23F ≥0.35μg/mL (Baseline)16 (12 to 21)22 (17 to 28)
1 Month post 3rd vaccination;PnC 23F92 (88 to 95)95 (92 to 97)
Statistical analysis
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: 0 · 95% CI -1 to 2
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -5 · 95% CI -12 to 1
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: 0 · 95% CI -2 to 2
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -4 · 95% CI -9 to 1
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -1 · 95% CI -5 to 2
  • rMenB All vs Routine · Miettinen and Nurminen · Vaccine group difference: -5 · 95% CI -11 to -1
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -1 · 95% CI -4 to 2
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -2 · 95% CI -5 to -1
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -1 · 95% CI -3 to 1
  • rMenB All vs Routine · Miettinen and Nurminen · Vaccine group difference: 0 · 95% CI -7 to 7
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -2 · 95% CI -4 to 0
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: 2 · 95% CI -4 to 8
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: 0 · 95% CI -2 to 1
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: 0 · 95% CI -4 to 3
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -1 · 95% CI -3 to 1
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: 0 · 95% CI -3 to 4
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -3 · 95% CI -8 to 2
SecondaryPercentages of Subjects With Fourfold Increase in Antibody Concentrations Against the Routine Antigens

Immunogenicity was assessed in terms of the percentages of subjects with fourfold increase in antibody concentrations against the routine pertussis antigens FHA (Filamentous Hemagglutinin), Pertactin and PT (Pertussis Toxoid).

Time frame:
5 months
Reported as:
Number · Percentages of Subjects
Percentages of Subjects With Fourfold Increase in Antibody Concentrations Against the Routine Antigens
Percentages of SubjectsrMenB AllRoutine
FHA84 (79 to 88)87 (82 to 91)
Pertactin79 (73 to 84)88 (84 to 92)
PT92 (88 to 95)95 (91 to 97)
Statistical analysis
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -3 · 95% CI -9 to 4
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -9 · 95% CI -16 to -3
  • rMenB All vs Routine · Miettinen and Nurminen · Percentage group difference: -2 · 95% CI -7 to 2
SecondaryPercentages of Subjects With Fourfold Rise in hSBA Titers After Three Doses of rMenB+OMV NZ Vaccination

Immunogenicity was assessed in terms of the percentages of subjects with fourfold rise in hSBA titers after the three doses of rMenB+OMV NZ (lot 1 or lot 2 or lot 3) vaccination at 2, 4 and 6 months of age.

Time frame:
1 Month after third vaccination
Reported as:
Number · Percentages of Subjects
Percentages of Subjects With Fourfold Rise in hSBA Titers After Three Doses of rMenB+OMV NZ Vaccination
Percentages of SubjectsrMenB Lot1rMenB Lot2rMenB Lot3rMenB AllRoutine
44/76-SL99 (97 to 100)100 (99 to 100)98 (97 to 99)99 (98 to 100)1 (0.023 to 5)
5/99100 (99 to 100)100 (99 to 100)99 (98 to 100)100 (99 to 100)2 (0 to 6)
NZ98/25470 (66 to 75)69 (64 to 74)75 (70 to 79)71 (69 to 74)1 (0.022 to 5)
SecondaryPercentage of Subjects With hSBA Titers ≥1:8

Immunogenicity was assessed in terms of the percentages of subjects achieving hSBA titers ≥1:8 at one month after third vaccination with rMenB (lot 1 or lot 2 or lot 3) against the three vaccine strains.

Time frame:
1 month after third vaccination
Reported as:
Number · Percentages of subjects
Percentage of Subjects With hSBA Titers ≥1:8
Percentages of subjectsrMenB Lot1rMenB Lot2rMenB Lot3rMenB AllRoutine
44/76-SL (Baseline)2 (1 to 4)2 (1 to 3)2 (1 to 4)2 (1 to 3)2 (0 to 6)
1 Month after 3rd vaccination-44/76-SL100 (99 to 100)100 (99 to 100)99 (98 to 100)100 (99 to 100)1 (0.022 to 5)
5/99 (Baseline)3 (1 to 5)3 (1 to 5)2 (1 to 4)3 (2 to 4)2 (0 to 6)
1 Month after 3rd vaccination-5/99100 (99 to 100)100 (99 to 100)99 (98 to 100)100 (99 to 100)2 (0 to 6)
NZ98/254 (Baseline)1 (0.063 to 2)1 (0 to 3)0 (0 to 1)1 (0 to 1)0 (0 to 3)
1 Month after 3rd vaccination70 (66 to 75)70 (65 to 74)75 (70 to 79)72 (69 to 74)1 (0.021 to 5)
SecondaryNumber of Subjects Reporting Solicited Adverse Events After Receiving Three Doses of rMenB+OMV NZ Vaccine

The safety and tolerability of three doses of rMenB+OMV NZ when given concomitantly with routine infant vaccines at 2, 4 and 6 months of age was assessed by the number of subjects reporting solicited local and systemic adverse events.

Time frame:
upto 7 days after any vaccination
Reported as:
Number · Participants
Number of Subjects Reporting Solicited Adverse Events After Receiving Three Doses of rMenB+OMV NZ Vaccine
ParticipantsrMenB AllMenC+Routine
Any Local2388443
Injection site tenderness2147266
Injection site erythema2049261
Injection site induration1908227
Injection site swelling117484
Any Systemic2450459
Change in Eating Habits1787257
Sleepiness2159353
Vomiting662116
Diarrhea1086164
Irritability2296370
Unusual Crying2109352
Rash31843
Fever >= 38.5C1912228
Others2302325
Medical Attend. Fever5716
Analg. Antipyretic Med.Used2302325
Antipyretic Med.Used2240314

Adverse events

Collected over All serious adverse events and medically attended adverse events are collected from Day 8 after each vaccination to next vaccination or to 30 days after the last vaccination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rMenB Lot1—70/832 (8.4%)827/832 (99.4%)
rMenB Lot2—80/828 (9.7%)825/828 (99.6%)
rMenB Lot3—60/820 (7.3%)817/820 (99.6%)
Routine—51/659 (7.7%)652/659 (98.9%)
MenC+Routine—28/490 (5.7%)482/490 (98.4%)
Most frequent serious events
Showing 10 of 111
Most frequent serious events
EventrMenB Lot1rMenB Lot2rMenB Lot3RoutineMenC+Routine
BronchitisInfections and infestations6/83212/8287/82011/6591/490
GastroenteritisInfections and infestations12/8327/82812/8207/6592/490
LaryngitisInfections and infestations7/8324/8283/8203/6590/490
Otitis mediaInfections and infestations3/8322/8286/8203/6590/490
PyelonephritisInfections and infestations1/8323/8286/8202/6590/490
Urinary tract infectionInfections and infestations2/8320/8281/8200/6593/490
BronchiolitisInfections and infestations4/8322/8285/8200/6592/490
BronchopneumoniaInfections and infestations1/8324/8281/8201/6590/490
Gastroenteritis rotavirusInfections and infestations3/8324/8281/8201/6592/490
PneumoniaInfections and infestations3/8324/8283/8202/6591/490
Most frequent other events
Showing 10 of 23
Most frequent other events
EventrMenB Lot1rMenB Lot2rMenB Lot3RoutineMenC+Routine
IrritabilityPsychiatric disorders769/832761/828766/820544/659370/490
Injection site painGeneral disorders736/832736/828728/820415/659358/490
Injection site erythemaGeneral disorders729/832733/828704/820497/659385/490
SomnolenceNervous system disorders714/832729/828716/820476/659353/490
CryingGeneral disorders714/832711/828685/820424/659352/490
Injection site indurationGeneral disorders692/832680/828664/820452/659390/490
PyrexiaGeneral disorders656/832646/828643/820319/659248/490
Eating disorderPsychiatric disorders588/832603/828596/820329/659257/490
Injection site swellingGeneral disorders440/832466/828436/820254/659184/490
DiarrhoeaGastrointestinal disorders370/832380/828368/820225/659168/490

Baseline characteristics

Age, Continuous
Age, Continuous(Days)rMenB Lot1rMenB Lot2rMenB Lot3RoutineMenC+ RoutineTotal
Mean73.8 ± 9.574.1 ± 9.673.3 ± 9.474.7 ± 9.370.6 ± 9.773.5 ± 9.5
Sex: Female, Male
Sex: Female, Male(Participants)rMenB Lot1rMenB Lot2rMenB Lot3RoutineMenC+ RoutineTotal
Female4034004163182341771
Male4304284043412561859
08

Study locations

66 sites
  • Grässl
    Hall in Tirol, 6060, Austria
  • Häckel
    Kirchdorf, 4560, Austria
  • Prieler
    Neufeld a.d. Leitha, 2491, Austria
  • Maurer
    Salzburg, 5020, Austria
  • Angermayr
    Wels, 4600, Austria
  • Sommer
    Wien, 1230, Austria
  • Site 27
    Boskovice, 680 01, Czechia
  • Site 19
    Brno, 628 00, Czechia
  • Site 22
    Chomutov, 430 03, Czechia
  • Site 14
    Děčín, 405 01, Czechia
  • Site 12
    Havlíčkův Brod, 580 22, Czechia
  • Site 8
    Hradec Králové, 500 01, Czechia
  • Site 9
    Hradec Králové, 500 05, Czechia
  • Site 28
    Hranice I-mesto, 753 01, Czechia
  • Site 13
    Humpolec, 396 01, Czechia
  • Site 15
    Jindřichův Hradec, 377 01, Czechia
  • Site 25
    Kladno 2, 272 00, Czechia
  • Site 21
    Kolín, 280 02, Czechia
  • Site 10
    Liberec, 460 15, Czechia
  • Site 24
    Litomerice, 412 01, Czechia
  • Site 18
    Ostrava-Poruba, 708 68, Czechia
  • Site 17
    Ostrava, 702 00, Czechia
  • Site 7
    Pardubice, 532 03, Czechia
  • Site 16
    Plzeň, 305 99, Czechia
  • Site 2
    Prague, 130 00, Czechia
  • Site 3
    Prague, 140 00, Czechia
  • Site 5
    Prague, 16000, Czechia
  • Site 6
    Prague, 19000, Czechia
  • Site 26
    Rumburk, 408 01, Czechia
  • Site 23
    Usti nad Labem, 400 01, Czechia
  • Site 20
    Znojmo, 669 00, Czechia
  • Site11
    Červený Kostelec, 54941, Czechia
  • Site 30
    Espoo, 02230, Finland
  • Site 31
    Helsinki, 00100, Finland
  • Site 32
    Helsinki, 00930, Finland
  • Site 34
    Järvenpää, 04400, Finland
  • Site 35
    Kokkola, 67100, Finland
  • Site 45
    Kotka, 48600, Finland
  • Site 46
    Kuopio, 70211, Finland
  • Site 47
    Lahti, 15140, Finland
  • Site 49
    Oulu, 90220, Finland
  • Site 50
    Pori, 28100, Finland
  • Site 51
    Seinäjoki, 60100, Finland
  • Site 52
    Tampere, 33100, Finland
  • Site 53
    Turku, 20520, Finland
  • Site 33
    Vantaa, 01300, Finland
  • Site 48
    Vantaa, 01600, Finland
  • Site 99
    Detmold, 32756, Germany
  • Site 92
    Espelkamp, 32339, Germany
  • Site 95
    Freising, 85354, Germany
  • Site 64
    Fulda, 36037, Germany
  • Site 58
    Lauffen, 74348, Germany
  • Site 57
    Marbach a. N., 74348, Germany
  • Site 97
    München, 81377, Germany
  • Site 96
    München, 81475, Germany
  • Site 91
    Műnchen, 81737, Germany
  • Site 81
    Porta Westfalica, 32457, Germany
  • Site 65
    Schwieberdingen, 71701, Germany
  • Site 94
    Weilheim, 82362, Germany
  • Dipartimento di Scienze della Salute
    Genova, 16132, Italy
  • Università degli Studi di Messina - Pad. NI - A.O.U. Policlinico G. Martino
    Messina, 98122, Italy
  • Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena Italia
    Milano, 20122, Italy
  • Pediatria dell' Ospedale Sacco
    Milano, 20157, Italy
  • Ospedale Maggiore della Carita'-Clinica Pediatrica
    Novara, 28100, Italy
  • Istituto di Igiene e Medicina Preventiva - Università degli Studi di Sassari
    Sassari, 07100, Italy
  • ASL/TA
    Taranto, 74100, Italy
09

References and documents

Publications

  • Zafack JG, Bureau A, Skowronski DM, De Serres G. Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. BMJ Open. 2019 May 19;9(5):e026953. doi: 10.1136/bmjopen-2018-026953. PubMed 31110098 ↗
  • Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; EU Meningococcal B Infant Vaccine Study group. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013 Mar 9;381(9869):825-35. doi: 10.1016/S0140-6736(12)61961-8. Erratum In: Lancet. 2013 Mar 9;381(9869):804. PubMed 23324563 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2015, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2008
First posted
Apr 14, 2008
Start
Mar 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Results first posted
Apr 10, 2015
Last update
Oct 10, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 10, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00657709
Lead sponsor
Novartis Vaccines
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 14, 2008
Start date
Mar 2008
Primary completion
Jan 2010
Completion
Jan 2010
Results posted
Apr 10, 2015
Last update
Oct 10, 2017

Study contacts

Novartis Vaccines
study chair · Novartis Vaccines

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion